Abstract
Galanin-like peptide (GALP) is a neuropeptide involved in the regulation of food intake behavior, body weight and energy metabolism. In previous studies, we demonstrated that the intranasal administration of GALP has weight loss effects, although the mechanism of this action was not clarified. The aim of this study was to demonstrate the functional significance of GALP on lipid metabolism in the liver. Mice were fed a high fat diet to cause diet-induced obesity (DIO) and then administered GALP intranasally for 2 weeks (experimental), or vehicle (control). Body weights, along with lipid levels in the plasma and liver, and lipid metabolism-related gene expression in the liver were subsequently measured. Body weight gain was decreased by the GALP treatment compared to the control group. Lipid droplet levels in hepatocytes and hepatic triglyceride levels were decreased in the GALP group compared with the vehicle group, whereas hepatic fatty acid β-oxidation-related gene mRNA levels were increased in the GALP group. These results suggest that the intranasal administration of GALP has an inhibitory effect on lipid accumulation in the liver.
Keywords: GALP, fatty liver, lipid metabolism, high fat diet, DIO, triglycerides.
Current Pharmaceutical Design
Title:Effect of Intranasal Administration of Galanin-like Peptide (GALP) on Body Weight and Hepatic Lipids Accumulation in Mice with Diet-induced Obesity
Volume: 23 Issue: 25
Author(s): Satoshi Hirako, Nobuhiro Wada, Haruaki Kageyama, Fumiko Takenoya, Hyounju Kim, Yuzuru Iizuka, Akiyo Matsumoto, Mai Okabe and Seiji Shioda*
Affiliation:
- Hoshi University School of Pharmacy and Pharmaceutical Sciences Global Research Center for Innovative Life Science, Peptide Drug Innovation, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501,Japan
Keywords: GALP, fatty liver, lipid metabolism, high fat diet, DIO, triglycerides.
Abstract: Galanin-like peptide (GALP) is a neuropeptide involved in the regulation of food intake behavior, body weight and energy metabolism. In previous studies, we demonstrated that the intranasal administration of GALP has weight loss effects, although the mechanism of this action was not clarified. The aim of this study was to demonstrate the functional significance of GALP on lipid metabolism in the liver. Mice were fed a high fat diet to cause diet-induced obesity (DIO) and then administered GALP intranasally for 2 weeks (experimental), or vehicle (control). Body weights, along with lipid levels in the plasma and liver, and lipid metabolism-related gene expression in the liver were subsequently measured. Body weight gain was decreased by the GALP treatment compared to the control group. Lipid droplet levels in hepatocytes and hepatic triglyceride levels were decreased in the GALP group compared with the vehicle group, whereas hepatic fatty acid β-oxidation-related gene mRNA levels were increased in the GALP group. These results suggest that the intranasal administration of GALP has an inhibitory effect on lipid accumulation in the liver.
Export Options
About this article
Cite this article as:
Hirako Satoshi , Wada Nobuhiro , Kageyama Haruaki, Takenoya Fumiko , Kim Hyounju, Iizuka Yuzuru , Matsumoto Akiyo , Okabe Mai and Shioda Seiji*, Effect of Intranasal Administration of Galanin-like Peptide (GALP) on Body Weight and Hepatic Lipids Accumulation in Mice with Diet-induced Obesity, Current Pharmaceutical Design 2017; 23 (25) . https://dx.doi.org/10.2174/1381612823666170321095950
DOI https://dx.doi.org/10.2174/1381612823666170321095950 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Micro-RNAs, Exercise and Cellular Plasticity in Humans: The Impact of Dietary Factors and Hypoxia
MicroRNA Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus
Current Cardiology Reviews The Effect of Sex and Gender on Diabetic Complications
Current Diabetes Reviews Metabolic Syndrome, its Pathophysiology and the Role of Melatonin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Regulation of G-Protein-Coupled Receptor Signalling by the Scaffolding Proteins Spinophilin/Neurabin 2 and Neurabin 1
Current Chemical Biology Glucagon-Like Peptide 1 and the Cardiovascular System
Current Diabetes Reviews Current and Future Drugs for Appetite Regulation and Obesity Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design Clinical Studies of Renal Nerve Ablation. Unanswered Questions for its Efficacy and Safety
Current Clinical Pharmacology Cardiovascular Risk in Perimenopausal Women
Current Vascular Pharmacology Molecular Mechanisms Involving Sigma-1 Receptor in Cell Apoptosis of BV-2 Microglial Cells Induced by Methamphetamine
CNS & Neurological Disorders - Drug Targets Pro Atrial Natriuretic Peptide (1-30) and 6-keto PGF<sub>1α</sub> Activity Affects Na<sup>+</sup> Homeostasis in Non-modulating Hypertension
Current Hypertension Reviews Hypoxia in Pre-Eclampsia: Cause or Effect?
Current Women`s Health Reviews The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Current Clinical Pharmacology Preclinical Development of New Therapy for Glycogen Storage Diseases
Current Gene Therapy Modulation of Retinal Arteriolar Central Reflection by APOE Genotype
Current Alzheimer Research Coronary Stent Fracture: A Recently Appreciated Phenomenon with Clinical Relevance
Current Cardiology Reviews Hypercortisolemia and Glucocorticoid Receptor-Signaling Insufficiency in Alzheimer’ s Disease Initiation and Development
Current Alzheimer Research Subject Index To Volume 6
Cardiovascular & Hematological Disorders-Drug Targets Preface [Hot Topic: Arachidonic Acid Cascade Modulators: The Cyclooxygenase Pathway (Executive Editors: Jean-Michel Dogné / Xavier de Leval)]
Mini-Reviews in Medicinal Chemistry